AcelleRX Therapeutics

AcelleRX Therapeutics is a clinical-stage biotechnology company focused on developing cell-based therapies for cardiovascular and ischemic diseases. Spun out of the University of California, San Francisco (UCSF), the company utilizes a proprietary platform to isolate and deliver autologous CD34+ cells to promote angiogenesis and tissue repair. Its lead candidate, ARX-101, has been evaluated in Phase 2 clinical trials for the treatment of refractory angina in patients who have exhausted standard revascularization options. Beyond cardiovascular health, AcelleRX is exploring the application of its cell therapy platform in other ischemic conditions, including chronic kidney disease. The company's mission is to harness the regenerative potential of the patient's own cells to restore blood flow and improve cardiac function.